Atlas Trials

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

Clinical trial NCT03443869 · COMPLETED

Trial details

NCT number
NCT03443869
Sponsor
Merck Sharp & Dohme LLC
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
CMV Disease
Start date
2018-05-03
Primary completion
2022-04-05
Enrollment
601

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.